Sanofi - Therapeutic Areas

A text call-out highlighting building on Sanofi's legacy to advance innovations in medicines to treat patients with multiple sclerosis. For over a decade, our mission has been to improve the lives of people with life-altering neuroinflammatory and neurodegenerative diseases.

Neurology R&D

Multiple sclerosis (MS) is a chronic, immune-mediated, neurodegenerative disease

Graphic of people standing over a U.S. map to represent the patient population with MS in the U.S.

The estimated adult population diagnosed with MS is ~800,000 persons^1-3

Inflammation and demyelination in the CNS lead to:

Irreversible axonal loss

Cognitive dysfunction

Brain volume loss

Long-term disability

FDA-approved product in Neurology

Illustration of a blister pack of pills.

Explore our FDA-approved product used to treat relapsing forms of MS

Product information

Exclusive, near-term disease spotlight for payers

Discover the unmet needs for multiple sources of damage in the
brain that contribute to progression of MS

Learn more

Explore individual pipeline clinical trials investigating:

Chronic inflammatory
demyelinating polyneuropathy
(CIDP)

Study design 1

Study design 2

Nonrelapsing secondary
progressive MS (nrSPMS)

Study design 1

Study design 2

Relapsing MS (RMS)

Study design

nrSPMS, primary progressive MS
(PPMS), or RMS

Study design

Illustration of an infusion bag and medical items including pills, an pill bottle, a syringe, and an infusion bag representing Sanofi's FDA-approved products.

Explore more therapeutic areas of focus in our specialty care portfolio